MARK2 and neoplasm: Meanwhile, sorafenib suppresses tumor angiogenesis and proliferation by inhibiting multikinases such as the serine/threonine kinase family (e.g., Raf-1, PI3K/Akt, ERK1/2, and STAT3) and the receptor tyrosine kinase family (e.g., FGFR, VEGFR, and PDGFR) [3].